The treatment involves stimulating the innate immune system to wake up, and clean up ALL pathogens in the body (kill all the bad bugs). The mechanism used to achieve this is by injecting components of dead E. coli bacteria into the skin (dendritic cells). The preliminary trial showed a promising remission rate so they moved into a full clinical trial for people with Crohn’s late last year. This new trial for UC is Phase 2.
Here’s an excerpt from a press release that we received about this new trial:
“Qu Biologics’ clinical trial in ulcerative colitis has been initiated at the GI Research Institute in Vancouver, the first of at least four clinical trial sites in Canada. In the coming weeks, three additional sites will open in Edmonton, Calgary and Hamilton. All participants in the study will receive QBECO SSI treatment.
Qu Biologics’ CEO Dr. Hal Gunn stated, “SSIs represent a promising new treatment option for inflammatory bowel disease designed to restore normal immune function rather than suppressing immune response.” He added, “In combination with results from our Phase 2 trial in Crohn’s disease expected in the first half of 2016, it is our hope that results from this ulcerative colitis clinical trial could provide further evidence supporting QBECO SSI as a potentially important new therapy for patients with inflammatory bowel disease.”Qu Biologics received a No Objection Letter (NOL) from Health Canada to proceed with the Phase 2 open-label, dose-ranging, proof-of-concept study to evaluate the safety, tolerability and efficacy of QBECO SSI for the treatment of patients with moderate-to-severe ulcerative colitis.”
For more information, here’s a link to the UC trial page at the Qu Biologics website:
Here’s a link back to the post Jini wrote about the Crohn’s trial which features an audio interview with Jini and Dr. Hal Gunn from Qu Biologics: